Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Intangibles (2018 - 2025)

Historic Change in Intangibles for Ultragenyx Pharmaceutical (RARE) over the last 6 years, with Q1 2025 value amounting to $15.0 million.

  • Ultragenyx Pharmaceutical's Change in Intangibles rose 5000.0% to $15.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $15.0 million, marking a year-over-year increase of 2000.0%. This contributed to the annual value of $12.5 million for FY2024, which is 40000.0% up from last year.
  • Ultragenyx Pharmaceutical's Change in Intangibles amounted to $15.0 million in Q1 2025, which was up 5000.0% from $2.5 million recorded in Q2 2024.
  • In the past 5 years, Ultragenyx Pharmaceutical's Change in Intangibles ranged from a high of $30.0 million in Q1 2022 and a low of $2.5 million during Q2 2023
  • Its 4-year average for Change in Intangibles is $12.0 million, with a median of $10.0 million in 2024.
  • In the last 5 years, Ultragenyx Pharmaceutical's Change in Intangibles changed by 0.0% in 2024 and then skyrocketed by 5000.0% in 2025.
  • Over the past 4 years, Ultragenyx Pharmaceutical's Change in Intangibles (Quarter) stood at $30.0 million in 2022, then tumbled by 91.67% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024, then skyrocketed by 500.0% to $15.0 million in 2025.
  • Its last three reported values are $15.0 million in Q1 2025, $2.5 million for Q2 2024, and $10.0 million during Q1 2024.